8-K: BioLife Solutions Reports Strong Q4 and Full Year 2024 Results, Projects Continued Growth in 2025

BioLife Solutions announces positive Q4 and full year 2024 financial results, driven by cell processing revenue growth, and provides optimistic 2025 revenue guidance.

Summary

• BioLife Solutions reported a 31% increase in total revenue for Q4 2024, reaching $22.7 million, compared to $17.4 million in Q4 2023.
• Cell Processing platform revenue increased by 37% to $20.3 million in Q4 2024 and 12% to $73.5 million for the full year.
• GAAP gross margin for Q4 2024 was 60%, while adjusted gross margin was 63%.
• The company reported a GAAP net loss from continuing operations of $2.0 million for Q4 2024 and an adjusted EBITDA of $4.0 million, representing 18% of total revenue.
• For the full year 2024, total revenue was $82.3 million, an 8% increase from $75.9 million in 2023.
• BioLife Solutions expects 2025 Cell Processing revenue to be between $86.5 million and $89.0 million, reflecting an 18% to 21% increase over 2024.
• Total revenue for 2025 is projected to be between $95.5 million and $99.0 million, a 16% to 20% increase over 2024.
• The company's cash, cash equivalents, and marketable securities totaled $109.2 million as of December 31, 2024.
• BioLife Solutions completed the sales of SciSafe and CBS in November 2024 for approximately $73.0 million and $6.1 million in cash, respectively.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth in the cell processing segment, improved gross margins, and optimistic guidance for 2025. The successful divestitures and healthy cash position further contribute to the positive sentiment.

Positives

• Strong growth in Cell Processing revenue, both sequentially and year-over-year.
• Improved GAAP gross margin compared to the previous year.
• Positive adjusted EBITDA, indicating profitability on a non-GAAP basis.
• Healthy cash position due to divestitures.
• Optimistic revenue guidance for 2025, projecting continued growth.
• Increase in FDA Master File cross references for biopreservation media.
• Expansion of biopreservation media into approved cell and gene therapies.

Negatives

• GAAP net loss from continuing operations for Q4 2024 and full year 2024.
• Evo and Thaw platform revenue decreased by 8% in Q4 2024 and 14% for the full year 2024.
• Adjusted EBITDA decreased as a percentage of revenue from 21% to 18% for Q4 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Dependence on the growth and success of the cell and gene therapy market.
• Competition from other suppliers of cell processing tools and services.
• Potential challenges in integrating new products and technologies into the portfolio.
• The company's ability to achieve projected revenue growth and profitability depends on various factors, including market conditions and customer demand.

Future Outlook

BioLife Solutions expects 2025 Cell Processing revenue to grow 18% to 21% and total revenue to increase by 16% to 20%. Management anticipates gross margin in the low 60% range (GAAP) and mid-60% range (non-GAAP), a reduction in net loss (GAAP), and continued expansion of adjusted EBITDA margin (non-GAAP).

Management Comments

• Roderick de Greef, Chairman and CEO, stated that 2024 was a pivotal year for BioLife, solidifying its position as a leading pure play enabler of cell and gene therapies.
• De Greef noted that the company delivered five consecutive quarters of revenue growth in its cell processing platform, exceeding expectations and outperforming raised full year guidance.
• De Greef highlighted the company's focus on optimizing its portfolio through divestitures to drive gross margin and adjusted EBITDA margin expansion.
• De Greef mentioned the potential to increase revenue per dose by two to three-fold by integrating tools into approved therapies.
• De Greef stated that the company remains focused on strategically enhancing its cell processing portfolio, both organically and inorganically, to strengthen market leadership and deliver long-term value.

Industry Context

BioLife Solutions operates in the rapidly growing cell and gene therapy (CGT) market. The company's focus on cell processing tools and services positions it to benefit from the increasing demand for these therapies. The company's strategy of divesting non-core assets and focusing on high-growth, high-margin products aligns with the industry trend of specialization and efficiency.

Comparison to Industry Standards

• When compared to companies like CryoPort, which also provides temperature-controlled supply chain solutions for the life sciences industry, BioLife Solutions' focus on cell processing tools and services offers a more specialized approach.
• While Thermo Fisher Scientific offers a broad range of products and services for the life sciences industry, BioLife Solutions' dedicated focus on cell and gene therapy provides a competitive advantage in this niche market.
• Compared to smaller, specialized companies, BioLife Solutions' established market presence and financial resources provide a strong foundation for continued growth and expansion.

Stakeholder Impact

• Shareholders can expect continued growth and profitability, driven by the company's focus on the cell and gene therapy market.
• Employees will benefit from the company's expansion and strategic investments in its core business.
• Customers will have access to innovative cell processing tools and services that support the development and commercialization of new therapies.
• Suppliers can expect continued demand for their products and services as BioLife Solutions expands its operations.
• Creditors can be confident in the company's financial stability and ability to meet its obligations.

Next Steps

• Management will discuss the financial results and provide a business update during a conference call and live webcast.
• The company will continue to focus on strategically enhancing its cell processing portfolio, both organically and inorganically.
• BioLife Solutions aims to deepen relationships with biopreservation customers and increase adoption of its broader cell processing product lines.
• The company expects 8 additional approvals, geographic expansions or new indications for therapies using their biopreservation media in the next 12 months.

Key Dates